The global diabetes management device system market is expected to grow at a CAGR of around 5.4% from 2019 to 2026 and expected to reach around US$ 12.0 Bn by 2026.
Diabetes is a metabolic disease that occurs when blood glucose, also called blood sugar, is too high for a prolonged period of time. The goal of diabetes management devices is to effectively control blood glucose level and minimizes the risk associated with long term diabetes. These devices include glucose monitoring devices and insulin delivering devices. Glucose monitoring devices include glucose test strips, lancets, and continuous glucose monitors. Furthermore, insulin delivering devices include an insulin pen, pumps, implants, and syringes. Technological advancements such as devices with USB port, Bluetooth, and bolus calculator are also entered into the global market. There are some diabetes management devices that measure blood ketones level.
Consistently growing geriatric population across the world, technological advancement in the field of diabetes management, the presence of several multinational as well as regional players in the industry, and R&D investment by market players are the key driving factors for the growth of the market. For instance, according to the World Health Organization, the number of patients with diabetes has risen to 422 million in 2014 from 108 million in 1980 across the world. The government initiatives to manage diabetes and increasing awareness about diabetes management devices among patients are also propel the market growth during the forecast period.
Several innovative devices such as the implantable glucose sensors and implantable continuous infusion devices are in pipeline and hence the expected entry of such devices in the market is anticipated to boost the market growth. However, the high cost of diabetes management devices is a key factor that may restrain the market growth in low-income countries.
Based on the product, the global diabetes management devices market has been segmented into monitoring devices and treatment devices. In 2018, the monitoring devices segment accounted for the largest share of the market. Monitoring devices further sub-segmented into blood glucose meters, continuous glucose monitoring devices, self-monitoring blood glucose systems, test strips, lancets, and others. Technological innovations and demand for continuous glucose monitoring devices and investment by key market players are the key factors for the dominance of the segment. For instance, in January 2019, Medtronic along with the Eris Lifesciences launched Guardian Connect, a first smart continuous glucose monitoring system across the world. Diabetes treatment devices further divided into insulin pen, insulin pumps, insulin jet injectors, insulin syringes, and others.
Distribution Channel Analysis
Based on the distribution channel, the market is divided into institutional sales and retail sales. Institutional sales consist of clinics, hospitals, and academic & research institutes, whereas, retail sales segment consists of retail pharmacies and online pharmacies. Institutional sales accounted for the largest share of the market in 2018 due to the large demand for volume and availability of large patient population.
Geographically the market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America held the largest share of the diabetes management device system market in 2018 and is anticipated to maintain its dominance during the forecast period. Entry and greater adoption of digital devices, local presence of market players, and the growing number of diabetic patients due to unhealthy lifestyle are the key factors for the dominance and the growth of the region. Europe held the second-largest region for the market. However, Asia Pacific is anticipated to observe the fastest growth during the forecast period. Presence of large targeted population, new product launches, and investment by market players due to large demand for products are the key factors for the growth of the market in the Asia Pacific region. For instance, according to the statistics published by the International Diabetes Federation in 2013, 60% of diabetic patients in the world live in Asia.
The market research study on “Diabetes Management Device System Market – Global Industry Analysis, Market Size, Opportunities and Forecast, 2019 – 2026”, offers a detailed insight on the global diabetes management device system market entailing insights on its different market segments. Market dynamics with drivers, restraints, and opportunities with their impact are provided in the report. The report provides insights into the global diabetes management device system market, its product, distribution channel, and major geographic regions. The report covers basic development policies and layouts of technology development processes. Secondly, the report covers global diabetes management device system market size and segment markets by products, distribution channel, and geography along with the information on companies operating in the market. The sample preparation market analysis is provided for major regional markets including North America, Europe, Asia Pacific, Latin America and Middle East and Africa. For each region, the market sizes for different segments have been covered under the scope of the report.
The players profiled in the report include Abbott, Bayer AG, Becton, Dickinson and Company, Hoffman-La Roche Ltd., Braun Melsungen AG, PHC Holdings Corporation, Medtronic, Novo Nordisk A/S, Sanofi, Tandem Diabetes Care, Inc., and DexCom, Inc. Most of the companies are focusing on the adopting new technologies and developing advanced products, partnerships, collaborations, and acquisitions for the geographical expansion and commercialization of products to enhance its share in the global diabetes management device system market.
By Distribution Channel
Middle East & Africa
Diabetes is a metabolic disease that occurs when blood glucose, also called blood sugar, is too high for a prolonged period of time.
The goal of diabetes management devices is to effectively control blood glucose level and minimizes the risk associated with long term diabetes.
Growing geriatric population across the world, technological advancement in the field of diabetes management, and R&D investment are the main driver of the diabetes management device system market.
According to Acumen Research and Consulting, the diabetes management device system market value is anticipated to be worth around US$ 12.0 billion in 2026.
The diabetes management device system market is anticipated to grow over 5.4% CAGR during the forecast period 2019 to 2026.
North America held maximum share in 2018 for diabetes management device system market.
Abbott, Bayer AG, Becton, Dickinson and Company, Hoffman-La Roche Ltd., Braun Melsungen AG, PHC Holdings Corporation, and Medtronic are the top players operating in the diabetes management device system market.